Reducing CNS-Active Medications to Prevent Falls and Injuries in Older Adults
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Medically Treated Falls |
328; 349 | 0.11 |
| SECONDARY Medication Discontinuation |
32; 40; 55; 49; 34; 23 | 0.183 |
Eligibility Criteria
Inclusion Criteria
- For opioid and sedative-hypnotic medications, eligible participants are aged 60 years or older, while for skeletal muscle relaxants, tricyclic antidepressants, and first-generation antihistamines, eligible participants are aged 65 years or older.
Eligible participants must be long-term users of the target medication, defined as pharmacy dispensing of at least one of the target medication classes for at least 70 of the prior 90 days.
Further, eligible participants must either be assigned to a primary care provider (PCP) or have had 1+ visits in the prior year with a PCP at one of the 18 Kaiser Permanente Washington clinics participating in the study.
Exclusion Criteria
- diagnosis of dementia or a prescription for a medication used to treat dementia (i.e., a cholinesterase inhibitor or memantine);
- residence in a skilled nursing facility;
- metastatic cancer diagnosis in the prior 12 months;
- receiving hospice or palliative care;
- legally blind (unable to read print materials);
- indication the participant requires a translator (cannot read materials printed in English); g) enrolled in other KPWA opioid deprescribing research studies;
h) enrolled in a KPWA pharmacy-driven initiative to reduce opioid doses; or i) diagnosed with opioid use disorder
Data sourced from ClinicalTrials.gov (NCT05689554). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.